

November 12, 2019

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director,

President and Chief Executive Officer

Notice of Instruction for Front-Loading Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment and Conclusion of Amendment Agreement

Tokyo, Japan, November 12, 2019 - SymBio Pharmaceuticals Limited (JASDAQ: 4582) announces that the instruction for front-loading exercise of the 47th stock acquisition rights, defined by the purchase agreement executed with EVO FUND, has been dispatched today. In addition, we hereby notify that we have concluded a Amendment Agreement with EVO FUND regarding the purchase agreement. By concluding the Amendment Agreement with EVO FUND, we enabled to designate the date to start exercise and the date where the whole commitment period begins by the instruction of front-loading exercise.

While our business is proceeding smoothly toward our 2021 profitalization plan, foracasted earnings for this year will be decreased because product shipment of TREAKISYM® from Astellas Deutschland GmbH is delayed due to quality issue. We found a need of additional capital for development and acquisition of global license of Brincidofovir, and purchase and buildup of stocks to establish an inhouse sales department in the next fiscal year. Under such circumstance, we decided to make an instruction of fonrt-loading exercise as a result of comprehensive considerastions of the recent stock price and other factors, beucase we believe there is a high possibility to raise capital enough for our business by making the intstruction at the time being.

1.	Name of stock acquisition rights	SymBio Pharmaceuticals Limited 47th stock acquisition rights
2.	Number of stock acquisition rights	15,000,000 units
3.	Number of shares to be issued	3,750,000 shares
4.	Date of instruction for front-loading exercise	November 12 th , 2019
5.	Date of exercise start	November 14 th , 2019

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.